retatrutide weight loss clinical trials results Eli Lilly infiltrates anti-obesity market as Phase III trial for begins retatrutide triple hormone receptor agonist

Primary Outcome: Hypersomnolence Our Primary outcome examined was incident hypersomnolence

doi:10.1016/j.bcp.2019.03.024 Yang L, Yang J, Pan T, Zhong X

My Digestion is SO much better A lot of people talk about the disappearance of food noise, and, yes, that has been amazing

What you do after hitting your goal weight determines whether you maintain your weight loss or end up back at the starting line

Amgens long-acting monthly obesity therapy MariTide (maridebart cafraglutide, formerly AMG 133) demonstrated substantial and sustained weight loss in a Phase II trial, with patients achieving an average of 20% weight loss without a plateau, along with cardiometabolic improvements, over 52 weeks